BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 10025900)

  • 1. Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?
    Broxterman HJ; Sonneveld P; Pieters R; Lankelma J; Eekman CA; Loonen AH; Schoester M; Ossenkoppele GJ; Löwenberg B; Pinedo HM; Schuurhuis GJ
    Leukemia; 1999 Feb; 13(2):258-65. PubMed ID: 10025900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia.
    Legrand O; Simonin G; Beauchamp-Nicoud A; Zittoun R; Marie JP
    Blood; 1999 Aug; 94(3):1046-56. PubMed ID: 10419897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells.
    Borg AG; Burgess R; Green LM; Scheper RJ; Liu Yin JA
    Br J Haematol; 2000 Jan; 108(1):48-54. PubMed ID: 10651723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different effects of metabolic inhibitors and cyclosporin A on daunorubicin transport in leukemia cells from patients with AML.
    Knaust E; Porwit-MacDonald A; Gruber A; Xu D; Peterson C
    Leuk Res; 2003 Feb; 27(2):183-91. PubMed ID: 12526924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy.
    Broxterman HJ; Sonneveld P; van Putten WJ; Lankelma J; Eekman CA; Ossenkoppele GJ; Pinedo HM; Löwenberg B; Schuurhuis GJ
    Leukemia; 2000 Jun; 14(6):1018-24. PubMed ID: 10865967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity.
    Broxterman HJ; Sonneveld P; Feller N; Ossenkoppele GJ; Währer DC; Eekman CA; Schoester M; Lankelma J; Pinedo HM; Löwenberg B; Schuurhuis GJ
    Blood; 1996 Jun; 87(11):4809-16. PubMed ID: 8639853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
    Tsimberidou AM; Paterakis G; Androutsos G; Anagnostopoulos N; Galanopoulos A; Kalmantis T; Meletis J; Rombos Y; Sagriotis A; Symeonidis A; Tiniakou M; Zoumbos N; Yataganas X
    Leuk Res; 2002 Feb; 26(2):143-54. PubMed ID: 11755464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.
    Leith CP; Kopecky KJ; Chen IM; Eijdems L; Slovak ML; McConnell TS; Head DR; Weick J; Grever MR; Appelbaum FR; Willman CL
    Blood; 1999 Aug; 94(3):1086-99. PubMed ID: 10419902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.
    List AF; Spier CS; Grogan TM; Johnson C; Roe DJ; Greer JP; Wolff SN; Broxterman HJ; Scheffer GL; Scheper RJ; Dalton WS
    Blood; 1996 Mar; 87(6):2464-9. PubMed ID: 8630412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells.
    Michieli M; Damiani D; Ermacora A; Raspadori D; Michelutti A; Grimaz S; Fanin R; Russo D; Lauria F; Masolini P; Baccarani M
    Br J Haematol; 1997 Feb; 96(2):356-65. PubMed ID: 9029025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes.
    Lepelley P; Poulain S; Grardel N; Preudhomme C; Cosson A; Fenaux P
    Leuk Lymphoma; 1998 May; 29(5-6):547-51. PubMed ID: 9643568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia.
    Michieli M; Damiani D; Ermacora A; Geromin A; Michelutti A; Masolini P; Baccarani M
    Br J Haematol; 2000 Mar; 108(4):703-9. PubMed ID: 10792272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML).
    van den Heuvel-Eibrink MM; Wiemer EA; Prins A; Meijerink JP; Vossebeld PJ; van der Holt B; Pieters R; Sonneveld P
    Leukemia; 2002 May; 16(5):833-9. PubMed ID: 11986944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P-glycoprotein (PGP), and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias.
    Damiani D; Michieli M; Ermacora A; Candoni A; Raspadori D; Geromin A; Stocchi R; Grimaz S; Masolini P; Michelutti A; Scheper RJ; Baccarani M
    Haematologica; 1998 Apr; 83(4):290-7. PubMed ID: 9592977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia.
    Ross DD; Wooten PJ; Sridhara R; Ordóñez JV; Lee EJ; Schiffer CA
    Blood; 1993 Aug; 82(4):1288-99. PubMed ID: 8102561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival.
    Borg AG; Burgess R; Green LM; Scheper RJ; Yin JA
    Br J Haematol; 1998 Dec; 103(4):1083-91. PubMed ID: 9886324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia.
    den Boer ML; Pieters R; Kazemier KM; Rottier MM; Zwaan CM; Kaspers GJ; Janka-Schaub G; Henze G; Creutzig U; Scheper RJ; Veerman AJ
    Blood; 1998 Mar; 91(6):2092-8. PubMed ID: 9490695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia.
    Gil L; Styczynski J; Dytfeld D; Debski R; Kazmierczak M; Kolodziej B; Rafinska B; Kubicka M; Nowicki A; Komarnicki M; Wysocki M
    Anticancer Res; 2007; 27(6B):4021-5. PubMed ID: 18225565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between the intracellular daunorubicin concentration, expression of major vault protein/lung resistance protein and resistance to anthracyclines in childhood acute lymphoblastic leukemia.
    Den Boer ML; Pieters R; Kazemier KM; Janka-Schaub GE; Henze G; Veerman AJ
    Leukemia; 1999 Dec; 13(12):2023-30. PubMed ID: 10602424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications.
    Michieli M; Damiani D; Ermacora A; Masolini P; Raspadori D; Visani G; Scheper RJ; Baccarani M
    Br J Haematol; 1999 Feb; 104(2):328-35. PubMed ID: 10050716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.